There is significant animal model data demonstrating a benefit of testosterone on both inflammatory and neuroprotective mechanisms relevant to multiple sclerosis (MS). Several studies have demonstrated lowered testosterone levels in up to 40% of men with MS. Lower testosterone levels were correlated with worsened scores of physical and cognitive disability. There is increasing data suggesting a role of testosterone in MS risk. A pilot study has demonstrated significant benefits of testosterone replacement therapy on cognitive, radiological, and immunological outcome measures in men with MS. Larger studies in other conditions have demonstrated concerns in terms of cardiovascular risk, which indicate the need for careful monitoring upon administration to MS patients. Further studies are needed to develop safer testosterone preparations, which preserve its multiple beneficial effects, as well as multicenter clinical trials to evaluate safety, dosing, and efficacy in larger populations of men with MS. Additionally, studies are needed to further explore the role of androgens as a risk factor for MS, particularly at key life transitions.
Introduction
Men are three times less likely to develop multiple sclerosis (MS) than women but are more likely to develop more severe phenotypes of MS. 1 These include a predilection to present with primary progressive MS 2 and increased an increased likelihood toward malignant MS. 3 In addition, men recover more poorly from relapses. 4 Males have increased rates of brain atrophy, disability accrual, and cognitive impairment, irrespective of disease type. 5, 6 In addition to chromosomal and epigenetic factors, gonadal hormones may contribute to sex-related differences in inflammation and neurodegeneration in MS. 7, 8 Age-related declines in male testosterone levels 9 have been hypothesized to partially explain the later onset of MS relative to women.
Androgens and testosterone cascade
Testosterone is the primary male sex hormone, and in males, testosterone acts through the androgen receptor. It has both anabolic effects including growth of muscle mass and bone maturation and androgenic effects, which include maturation of the sex organs and development of male secondary sex characteristics. Testosterone is synthesized from cholesterol through a cascade of enzyme reactions. Testosterone is reduced by 5-alpha-reductase to 5-alpha-dihydrotestosterone (5-DHT), which has five times the androgenic potency of testosterone. DHT, in contrast to testosterone, cannot be converted to estrogen through aromatases.
Biological actions relevant to MS
MS is primarily a Th1-mediated autoimmune disease. In vitro, addition of testosterone has been shown to induce an immune shift from Th1 to Th2, production of higher levels of interleukin (IL)-5 and IL-10 and decreased levels of interferon-gamma (IFNγ), 10 and to decrease the production of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α and IL-1β by human macrophages 11 and monocytes. 8, 12 In vivo, in experimental autoimmune encephalomyelitis (EAE), the animal model for MS, testosterone treatment has shown a similar Th2 shift. 13 Treatment of castrated SJL EAE mice with testosterone lowered IFNγ and increased IL-10 expression in lymph nodes and spleen. 14 SJL mice showed a decrease in adoptive EAE clinical disease when injected with T lymphocytes pretreated with testosterone versus untreated T lymphocytes. 10 Testosterone-treated cell lines produced less IFN-gamma and more IL-10 than untreated cell lines.
Testosterone may exert neuroprotective effects which may be important in MS pathogenesis. 15 Putative mechanisms include (1) its ability to cross the bloodbrain barrier in its free form and directly influence neuronal cells, 16 (2) protection of spinal cord neurons from glutamate toxicity 17 and protection from oxidative stress in neuronal cell lines, 18, 19 (3) an increase in the expression of neurotrophic factors such as brainderived neurotrophic factor (BDNF), 20 and (4) microglia activation is reduced in male mice with EAE supplemented with testosterone. 21 The same study showed that testosterone treatment administered either before or after disease induction restored excitatory synaptic transmission as well as presynaptic and postsynaptic protein levels within the hippocampus. Using a lysolecithin model, investigators found that testosterone and androgen receptors are required for spontaneous remyelination. 22 
Role of testosterone in MS risk
Testosterone levels measured at different periods of life have been studied in MS and generally support the hypothesis that reduced testosterone is a risk factor for MS in males. There are limited studies of testosterone in females, primarily because of the insensitivity of assays to the lowered levels of androgens typically seen in females.
MS risk-testosterone in the prenatal period
There is increasing evidence suggesting that the prenatal period may be a period of vulnerability to subsequent inflammatory and neurological diseases including MS. 23 Testosterone is produced by the fetus in utero both in first 6 weeks as well as in the second trimester. 24 The ratio of the lengths of the second and fourth fingers (2D:4D ratio) in males is highly influenced by the ratio of prenatal androgen to estrogen levels. 25 This sexually dimorphic ratio can be considered as a lifelong signature of prenatal hormonal levels: a higher ratio has been shown to be associated with a lower in utero balance of androgens to estrogen. In a cohort of 120 men with MS, we found a lowered 2D:4D ratio in men with MS compared to controls, reflecting lowered prenatal testosterone levels and supporting a role for lowered testosterone as a risk factor for MS. 26 
MS risk-testosterone at puberty
Puberty is heralded by suppression and then reactivation of the luteinizing hormone-releasing hormone (LHRH) pulse generator. The elevated amplitude in LHRH pulsatile discharges, in turn, leads to stimulation of pituitary gonadotropes named as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Pituitary gonadotropes start the process of gonadarche that is one of the main three components of puberty-neuroendocrine events, that is, (1) adrenarche, (2) gonadarche, and (3) activation of the growth axis. 27 Overall, gonadarche is initiated by the activation of the hypothalamic-pituitary-gonadal axis and accomplished by reaching the reproductive competence. In females, it is characterized by production of ovarian androgens from follicular theca cells, as well as estradiol and progesterone before and after ovulation, respectively. In males, it is characterized by production of androgens from testicular Leydig cells. 28 Adrenarche that is the activation of hypothalamic-pituitary-adrenal axis usually starts before gonadarche by a rise in adrenal androgens. Adrenal androgen levels will peak in the early 20s and are responsible in part for the secondary sexual features.
There is increasing evidence that obesity during adolescence is associated with a higher risk of MS in adults. [29] [30] [31] [32] [33] In children, one study found an effect of obesity in girls but not in boys; 34 however, a smaller number of male cases may have limited the ability to detect an effect. A higher body mass index (BMI) during adolescence may be associated with younger age at MS onset in women. 35 We evaluated the association and interactions of sexual maturity markers and obesity in a large cohort of children and adolescents with MS to evaluate effects on risk of pediatric MS and age at MS onset. 36 Using markers of sexual development, we found that pre-pubertal onset of MS is rare, with only 11% of girls and 15% of boys classified as Tanner stage I at onset. Only 20% of girls were pre-menarcheal at MS onset, suggesting that the onset of puberty may be a key turning point for the onset of MS. 37 Earlier age at pubarche, which requires a testosterone surge by the adrenals and/or testes, was associated with earlier age at MS onset in boys in our study. Interestingly, the more sexually mature boys were also more obese. Obesity alone was associated with increased risk of MS in both boys and girls. In males, higher BMI is typically associated with greater peripheral conversion of adrenal and gonadal androgens to estrogens (estrone and estradiol, respectively) in adipose tissue, consistent with a role of circulating estrogens in MS pathogenesis. 38 Leptin which is produced by adipose tissue and is a marker of satiety continues to rise after puberty in females, but its increase is suppressed in males due to the influence of testosterone. 37, 39 MS risk-testosterone levels in adult males Several studies have found decreased levels of testosterone in men with MS relative to healthy controls, although confounding can be introduced by an effect of chronic disease on hypogonadism. 40 In one study of 68 adult male MS patients, relative to 48 controls means levels of testosterone were significantly lower (p = 0.01) and consistent with hypogonadotropic hypogonadism. 41 In another study of 25 men with MS and 18 controls, testosterone levels were lower in the men with MS but not significantly so. 42 Estradiol levels correlated with radiologic burden of disease in the men, and testosterone levels correlated with magnetic resonance imaging (MRI) in the female patients. In the third study of 25 men with MS, testosterone levels were low in 24% of the patients. 43 We found in a cohort of 96 men who were in the early stages of disease that 40% had testosterone levels in the one percentile range of normal. 44 There was no compensatory rise in LH, suggesting that this is a central deficiency of testosterone. A study which used national databases and record linkage found a strong positive association between testicular hypofunction and subsequent MS (rate ratio = 4.62, 95% confidence interval (CI) = 2.3-8.24, p < 0.0001). 45 
Testosterone in MS disease course
In our cohort study of 96 men, we found that low total testosterone levels as well as testosterone/estradiol levels were associated with increased disability (Expanded Disability Status Scale (EDSS)) scores, as well as worsening cognitive decline measured by Symbol Digit Modalities Test (SDMT). 44 In a followup study, we demonstrated the same findings, controlling for vitamin D levels as well as leptin as an adiposity marker (Bove, under review).
Testosterone as a therapy
Desirable effects of testosterone supplementation in hypogonadal men include virilization/improvement in libido and energy, increased muscle strength and fat-free mass in hypogonadal and eugonadal young (19-35 years) and older men (60-75 years), and improved bone density. 46 All of these effects would be expected to counter the progressive clinical decline, marked by loss of walking ability, in patients with progressive MS. In the arena of cognition, testosterone treatment has been reported to improve visuospatial and working memory in healthy older men with and without hypogonadism and may protect against cognitive decline and dementia. 47, 48 Confidence interval (CI) is one of the major factors associated with unemployment in persons with MS and may affect function in all spheres of activities of daily living.
Testosterone replacement is widely used as a therapy in aging and hypogonadal men. While it may worsen preexisting prostate cancer in some men, there is no clear evidence that higher levels of circulating testosterone, within the physiological range, are linked to an increased risk of prostate cancer. Regular prostatespecific antigen monitoring, as well as a urological evaluation, is required for safety monitoring. Additionally, testosterone supplementation can cause erythrocytosis, with potential consequences including vascular sludging and thrombotic events, and thus, hematocrit levels should be monitored regularly. 49, 50 Preparations of testosterone include gels, pills, and topical solutions. Most are of unmodified/nonesterified forms of testosterone. In addition to testosterone itself, several ester prodrugs of testosterone are available in oil solutions for intramuscular injection. There are also synthetic anabolic steroids, including fluoxymesterone and oxandrolone which are given orally. DHT is not available in the United States. Most studies evaluating testosterone in MS or other diseases have utilized a gel form of nonesterified testosterone. Because some of the benefits of testosterone in EAE models may result from its aromatization to estradiol, testosterone preparations, as opposed to the downstream DHT product, have been initially explored. However, a recent study in EAE demonstrated a benefit of DHT, 51 obviating the need for further comparative studies.
The Testosterone Trials are a set of seven overlapping federally funded yearlong clinical trials conducted at 12 sites across the United States designed to evaluate the safety and efficacy of testosterone in a well-controlled setting for several conditions. The trials involved 790 men aged 65 years and older with low levels of testosterone caused by aging, as well as symptoms that could be related to low testosterone such as sexual problems, fatigue, muscle weakness, or impaired memory and cognition. These trials had varied outcomes: The anemia trial demonstrated a significant improvement with testosterone treatment in red blood cell levels in men with anemia with known causes and unexplained anemia. For the bone trial, after 1 year, participants experienced significantly increased bone mineral density and estimated bone strength. In the cardiovascular trial, the researchers found that the volume of arterial plaque increased significantly more in the testosterone-treated group compared to the untreated control group. 52 For the cognition trial, after a year of treatment, there was no significant change in verbal memory, visual memory, or problem solving. 53 In a pilot clinical trial in humans with MS, 10 male MS patients aged <65 years were treated with 10 g of gel containing 100 mg of testosterone in a cross-over design (6-month observation period followed by 12 months of treatment). 54 Clinical measures of disability and cognition (the Multiple Sclerosis Functional Composite and the 7/24 Spatial Recall Test) were obtained every 3 months. Monthly MRI measures of enhancing lesion activity and whole brain volumes were acquired. In addition, blood was drawn every 3 months during the entire study period for immunological studies. Treatment with testosterone gel was well tolerated and associated with improvement in cognitive performance as measured by the Paced Auditory Serial Addition Task, a test of processing speed and attention widely used in MS. In addition, treatment was associated with a slowing of brain atrophy as measured by MRI. There was no significant effect of testosterone treatment on gadoliniumenhancing lesions. 54 Testosterone treatment also significantly reduced delayed type hypersensitivity (DTH) skin recall responses, a functional in vivo measure of inflammatory immune responses, and induced a shift in peripheral lymphocyte composition by decreasing CD4 + T cells and increasing natural killer (NK) cells. 55 In addition, peripheral blood mononuclear cell (PBMC) production of IL-2 was significantly decreased, while TGF-β1 production was increased. Furthermore, PBMCs obtained during the treatment period produced significantly more BDNF and platelet-derived growth factor-BB (PDGF-BB). The concentrations of BDNF and PDGF-BB in PBMC cultures were in the biologically active range as shown by their ability to reduce glutamate-induced neuronal cell death in vitro. These results are consistent with an immunomodulatory as well as a potentially neuroprotective effect of testosterone treatment in MS.
Conclusion
There is significant animal model data demonstrating a benefit of testosterone on both inflammatory and neuroprotective mechanisms relevant to MS. Several studies have demonstrated lowered testosterone levels in up to 40% of men with early MS and correlation with disability scores including cognition. There is increasing data suggesting a role of testosterone in MS risk. A pilot study has demonstrated significant benefits of testosterone replacement therapy for cognitive and brain atrophy in men with MS and improvement in immune mechanisms that follow mechanisms identified in in vitro and animal data. Larger studies in other conditions have demonstrated concerns in terms of cardiovascular risk, which obviate the need for careful monitoring for administration to MS patients. Further studies are needed to develop safer testosterone preparations, which preserve its multiple beneficial effects, as well as multicenter clinical trials to evaluate safety, dosing, and efficacy in larger populations of men with MS. Additionally, studies are needed to further explore the role of androgens as a risk factor for MS, particularly at key life transitions.
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